Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SRPT

Sarepta Therapeutics Inc

Sep 12 • 04:00PM ET

17.39

-0.52 -2.90 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN ALNY IONS PFE PTCT EXEL PRTA BLUE RDUS

| Held by: IJR VTI VB XBI FBT VBK VXF SPSM IJT IBB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.76	Insider Own	5.50%	Shs Outstand	97.71M	Perf Week	-7.06%
Market Cap	1.70B	Forward P/E	6.79	EPS next Y	2.56	Insider Trans	0.00%	Shs Float	92.34M	Perf Month	-14.75%
Enterprise Value	2.25B	PEG	-	EPS next Q	-0.64	Inst Own	88.01%	Short Float	22.00%	Perf Quarter	-53.39%
Income	-57.96M	P/S	0.68	EPS this Y	-271.62%	Inst Trans	-7.91%	Short Ratio	1.57	Perf Half Y	-82.32%
Sales	2.48B	P/B	1.25	EPS next Y	168.42%	ROA	-1.63%	Short Interest	20.31M	Perf YTD	-85.70%
Book/sh	13.89	P/C	2.12	EPS next 5Y	4.48%	ROE	-4.76%	52W High	138.81 -87.47%	Perf Year	-86.30%
Cash/sh	8.19	P/FCF	-	EPS past 3/5Y	- -	ROIC	-2.14%	52W Low	10.41 66.97%	Perf 3Y	-84.00%
Dividend Est.	-	EV/EBITDA	40.01	Sales past 3/5Y	39.42% 37.94%	Gross Margin	77.63%	Volatility	5.23% 6.02%	Perf 5Y	-87.28%
Dividend TTM	-	EV/Sales	0.91	EPS Y/Y TTM	-221.56%	Oper. Margin	-0.04%	ATR (14)	1.27	Perf 10Y	-50.61%
Dividend Ex-Date	-	Quick Ratio	1.81	Sales Y/Y TTM	64.89%	Profit Margin	-2.34%	RSI (14)	43.78	Recom	2.86
Dividend Gr. 3/5Y	- -	Current Ratio	2.89	EPS Q/Q	2662.81%	SMA20	-7.70%	Beta	0.49	Target Price	23.96
Payout	0.00%	Debt/Eq	1.00	Sales Q/Q	68.38%	SMA50	-2.02%	Rel Volume	0.27	Prev Close	17.91
Employees	1372	LT Debt/Eq	1.00	Earnings	Aug 06 AMC	SMA200	-73.49%	Avg Volume	12.95M	Price	17.39
IPO	Jun 04, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	127.08% 15.16%	Trades		Volume	3,477,231	Change	-2.90%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-29-25	Upgrade	Oppenheimer	Perform → Outperform	$37
Jul-29-25	Upgrade	JP Morgan	Underweight → Neutral	$24
Jul-29-25	Upgrade	Barclays	Underweight → Equal Weight	$22
Jul-29-25	Reiterated	H.C. Wainwright	Sell	$5
Jul-29-25	Initiated	Bernstein	Mkt Perform	$13
Jul-28-25	Downgrade	Barclays	Equal Weight → Underweight	$10
Jul-25-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-24-25	Initiated	Citigroup	Sell	$7
Jul-23-25	Downgrade	BofA Securities	Neutral → Underperform	$10
Jul-22-25	Downgrade	Barclays	Overweight → Equal Weight	$18
Jul-21-25	Downgrade	UBS	Buy → Neutral	$12
Jul-21-25	Downgrade	Needham	Hold → Underperform
Jul-21-25	Downgrade	Mizuho	Outperform → Neutral	$14
Jul-21-25	Downgrade	Leerink Partners	Outperform → Market Perform	$10
Jul-21-25	Downgrade	Deutsche Bank	Buy → Hold	$9
Jul-18-25	Downgrade	Needham	Buy → Hold
Jun-20-25	Downgrade	William Blair	Outperform → Mkt Perform
Jun-18-25	Downgrade	TD Cowen	Buy → Hold	$24
Jun-17-25	Initiated	Wolfe Research	Peer Perform
Jun-16-25	Downgrade	Piper Sandler	Overweight → Neutral	$36

Show Previous Ratings

Sep-05-25 09:30AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
09:00AM	Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year (Business Wire)
Sep-03-25 07:27AM	Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results (Insider Monkey)
Aug-28-25 08:21AM	Cell and gene therapies on correction course but not sinking (Pharmaceutical Technology)
Aug-26-25 06:15PM	Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 (PR Newswire)
11:33AM	Loading…
Aug-23-25 11:33AM	Credit Fuels the AI Boom and Fears of a Bubble (Bloomberg)
Aug-21-25 12:13PM	Walmart weighs on Dow, Sarepta debt restructuring (Yahoo Finance Video)
09:33AM	Sarepta Gets Breathing Room in $700 Million Debt Restructure (Bloomberg)
07:00AM	Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027 (Business Wire)
06:56AM	Sarepta pushes off debt payments in bid to regain financial footing (BioPharma Dive)
Aug-20-25 11:37PM	Jim Cramer on Sarepta Therapeutics: "If it Goes Up, You Gotta Do Some Selling" (Insider Monkey)
11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com)
Aug-18-25 09:03AM	Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your Rights - Contact Levi & Korsinsky Before August 25, 2025 (Newsfile)
07:00AM	How the Moms and Dads of Patients Won Sareptas Drug a Reprieve (Bloomberg)
Aug-15-25 09:15AM	Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT (PR Newswire) +7.44%
09:00PM	Loading…
Aug-14-25 09:00PM	Lightning Round: I don't have a positive outlook on Sarepta, says Jim Cramer (CNBC TV)
04:18PM	Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives (Investor's Business Daily)
11:41AM	Sarepta Sells Biotech Stake to Raise Cash as Elevidys Troubles Hit Home (Barrons.com)
11:24AM	Sarepta Sells Arrowhead Stake to Fund Milestone Payment (Zacks)
07:29AM	Sarepta sells Arrowhead shares as partnership, debt payments loom (BioPharma Dive)
Aug-13-25 04:12PM	Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment (Business Wire) +8.51%
04:10PM	Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics (Business Wire)
Aug-12-25 03:33PM	Brutal 2025 for Sarepta-Analysts Still Call for 179% Upside (MarketBeat)
07:17AM	Prasads shock FDA return reignites regulatory uncertainty (Pharmaceutical Technology)
Aug-11-25 04:40PM	These Stocks Moved the Most Today: C3.ai, Coinbase, Monday.com, Avantor, Tegna, Nvidia, Albemarle, and More (Barrons.com)
03:24PM	Leadership Turmoil at FDA Adds to Difficult Stretch for Biotech Investors (Barrons.com)
11:06AM	These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Avantor, Tegna, Nvidia, Albemarle, and More (Barrons.com)
11:01AM	Controversial FDA regulator back 12 days after resigning (Quartz)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
06:22AM	Wall St futures steady, chip stocks slip on China sales deal (Reuters)
06:09AM	Loading…
06:09AM	Nvidia and AMD shares dip, and other movers (MarketWatch)
05:26AM	These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More (Barrons.com)
Aug-08-25 05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive)
04:00AM	As gene therapies falter on the market, this biopharma is aiming to defy the odds (Pharma Voice)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +10.46%
09:29AM	Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries (Zacks)
Aug-06-25 07:00PM	Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:45PM	Sarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:45PM	Sarepta Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments (Business Wire)
Aug-04-25 11:07AM	Sarepta to Report Q2 Earnings: What's in Store for the Stock? (Zacks) +7.48%
08:30AM	Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer (GlobeNewswire)
Jul-31-25 06:22PM	493 employees laid off at biopharmaceutical company with operations in Andover (Andover Townsman, Mass.)
01:53PM	George Tidmarsh to sub in as FDA CBER head following Prasads shock exit (Pharmaceutical Technology)
10:00AM	Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know (Zacks)
08:48AM	Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results (Business Wire)
06:38AM	Markets Are Being Driven by AI, Not the Fed. Where Stocks Go From Here. (Barrons.com)
04:05AM	Stock Market News, July 30, 2025: U.S., Korea Reach Trade Deal; Powell Signals Reluctance to Cut Rates (The Wall Street Journal)
Jul-30-25 01:14PM	Top FDA Official's Surprise Departure Means More Uncertainty for Biotech (Barrons.com) +5.81%
10:00AM	Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth (Zacks)
09:36AM	Stocks to Watch Wednesday: Hershey, GE HealthCare, Starbucks, SoFi (The Wall Street Journal)
06:02AM	Starbucks stock jumps after earnings, and other early market movers (MarketWatch)
05:23AM	Stocks to Watch Wednesday: Visa, Starbucks, Meta, SoFi (The Wall Street Journal)
Jul-29-25 05:32PM	Sarepta Stock Soars After FDA Says It Can Resume Drug Shipments (Investor's Business Daily) +14.21%
05:11PM	These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More (Barrons.com)
03:38PM	Sarepta Therapeutics, Inc. (SRPT): "You Don't Court Homicide," Says Jim Cramer (Insider Monkey)
03:01PM	These Stocks Are Moving the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More (Barrons.com)
02:47PM	Sarepta finally gets some good news: A patient death wasn't its DMD drug's fault. (MarketWatch)
01:54PM	Squawk Pod: Commerce Secretary Lutnick & a midtown tragedy - 07/29/25 Audio Only (CNBC TV)
10:49AM	PayPal, Sarepta, JetBlue: Trending Tickers (Yahoo Finance Video)
10:16AM	Sarepta Therapeutics Stock Surges as FDA Allows Elevidys Sales to Resume (Investopedia)
07:21AM	Sarepta shares rebound after shipments of gene therapy Elevidys resume in US (Reuters)
06:50AM	Sarepta can begin shipping Elevidys therapy after FDA reverses pause, stock soars (Yahoo Finance)
05:27AM	These Stocks Are Moving the Most Today: Sarepta, Whirlpool, VeriSign, Cadence Design, Exelixis, UnitedHealth, and More (Barrons.com)
05:22AM	Sarepta surges, Whirlpool sinks, and other early market movers (MarketWatch)
05:01AM	Sarepta Stock Just Soared 45%. Here's Why. (Barrons.com)
Jul-28-25 06:38PM	Sarepta will resume gene therapy shipments after FDA review of recent patient death (Associated Press Finance) +16.18%
05:17PM	Sarepta Therapeutics gets FDA green light to resume Elevidys for DMD (Investing.com)
05:09PM	FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy (Business Wire)
04:55PM	Stocks Hold at Record, Dollar Jumps on Trade Hopes: Markets Wrap (Bloomberg)
04:34PM	Healthcare earnings: UnitedHealth delays, Sarepta's FDA probe (Yahoo Finance Video)
11:11AM	BMO Capital Cuts Sarepta Therapeutic (SRPT) PT to $25 from $50 (Insider Monkey)
09:54AM	Sarepta Stock Rises Despite Downgrade and FDA Probe. The Crisis Explained. (Barrons.com)
08:48AM	FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys (Benzinga)
07:30AM	Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics (Business Wire)
05:46AM	Sarepta Stock Drops After Downgrade and FDA Probe. The Crisis Explained. (Barrons.com)
Jul-25-25 07:51PM	Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS (Business Wire) -7.38%
04:16PM	Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe (Investor's Business Daily)
11:30AM	CHMP rejects Elevidys in latest setback for Sarepta (Pharmaceutical Technology)
11:05AM	Stock Market Today: S&P 500 Notches Fifth Consecutive Record Close as Vanguard, Goldman Warn On Growth (TheStreet)
08:34AM	Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union (Business Wire)
07:35AM	Sarepta stock falls after Elevidys fails to get backing by EU regulators (Investing.com)
07:08AM	SRPT STOCK NOTICE: Sarepta Therapeutics, Inc. Investors are Notified the Company is being Sued for Fraud and to Contact BFA Law by August 25 (Newsfile)
Jul-24-25 04:29PM	The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.' (Investor's Business Daily)
04:04PM	Stocks Close at Record as Alphabet Fuels AI Hopes: Markets Wrap (Bloomberg)
10:37AM	Sarepta Therapeutics (SRPT): "They Should Be Prosecuted," Says Jim Cramer (Insider Monkey)
07:40AM	Is This Stock a Buy After Soaring by 20% in 1 Day? (Motley Fool)
Jul-23-25 05:07PM	Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause (Yahoo Finance)
03:57PM	Sarepta Therapeutics, Inc. (SRPT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 25, 2025 (Newsfile)
09:41AM	Shopify and Unity downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics (Business Wire)
03:00AM	Sarepta's Troubles Show Risk, Investor Opportunity in Biotech Convertible Bonds (Barrons.com)
Jul-22-25 04:05PM	Sarepta Makes A 'Painful' Decision. Will It Help Rebuild Investors' Confidence? (Investor's Business Daily)
12:41PM	Why Sarepta's halted drug Elevidys is an issue for investors (Yahoo Finance Video)
12:33PM	Health Care Roundup: Market Talk (The Wall Street Journal)
10:22AM	Sarepta Faces Fresh Setback. Why Nows Not the Time to Buy the Stock. (Barrons.com)
10:15AM	Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy (Associated Press Finance)
09:40AM	Netflix downgraded, Intel initiated: Wall Street's top analyst calls (The Fly)
09:33AM	SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny (Zacks)
09:09AM	Morning Movers: Cleveland-Cliffs rallies after second quarter earnings release (TipRanks)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sarepta Therapeutics, Inc.	Shareholder	Aug 13 '25	Proposed Sale	19.99	9,265,312	185,213,587		Aug 13 08:55 PM
Barry Richard	Director	May 16 '25	Option Exercise	32.63	12,350	402,981	2,966,667	May 19 07:32 AM
Barry Richard	Director	May 13 '25	Option Exercise	19.23	20,246	389,359	2,954,317	May 15 07:00 AM
Nicaise Claude	Director	Mar 12 '25	Option Exercise	25.18	9,746	245,404	30,303	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Sale	99.64	2,491	248,203	27,812	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Proposed Sale	99.65	2,491	248,226		Mar 12 05:33 PM
Estepan Ian Michael	Chief Financial Officer	Jan 29 '25	Option Exercise	12.00	15,800	189,600	49,496	Jan 31 08:30 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Option Exercise	13.71	10,500	143,955	33,340	Dec 16 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Sale	124.84	10,500	1,310,820	22,840	Dec 16 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Proposed Sale	124.80	10,500	1,310,400		Dec 12 05:06 PM
Boor Kathryn Jean	Director	Dec 05 '24	Sale	125.55	1,636	205,400	5,880	Dec 06 08:00 PM
Boor Kathryn Jean	Director	Dec 05 '24	Proposed Sale	125.55	1,636	205,400		Dec 05 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRPT

Sarepta Therapeutics Inc

Upgrade your FINVIZ experience